Nathaniel M. Schuster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathaniel M. Schuster has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Ameet S. Nagpal
Medical University of South Carolina College of Medicine, Charleston, SC, USA
5 shared publications - Stephan Klessinger
Neurochirurgie Biberach, Biberach, Germany
4 shared publications Zachary L McCormick
Department of Physical Medicine and Rehabilitation, University of Utah School of Medicine , Salt Lake City, UT
4 shared publicationsAmitabh Gulati
Department of Anesthesiology, Memorial Sloan Kettering Cancer Center , New York, NY
3 shared publications- Belinda Duszynski
International Pain and Spine Intervention Society, Hinsdale, IL, USA
3 shared publications - Byron J. Schneider
Department of Physical Medicine and Rehabilitation, Vanderbilt University Medical Center, Nashville, TN, USA
3 shared publications
Latest Publications
- 26 October 2026
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
Nociplastic Questionnaire (NociQ)
Objectives: Nociplastic pain is implicated in many chronic pain conditions, yet it has been defined primarily by the absence of structural causes—a diagnosis by exclusion. No validated nociplastic pain questionnaire exists. This study examined hypothesized pain-specific features of nociplastic pain and developed a brief self-report instrument, the Nociplastic Questionnaire (NociQ). Methods: We generated items based on literature review and input from experts and individuals with lived experience. We administered the items and measures of other pain-related constructs (pain intensity/interference, catastrophizing, kinesiophobia, and perceived stress) to 888 participants with diverse chronic pain conditions. Results: Factor analyses supported four dimensions captured by internally consistent 4-item subscales (αs ≥0.74): 1) location variability, 2) exacerbation by thoughts and emotions, 3) widespreadness, and 4) allodynia. The NociQ total score adequately discriminated presumed nociplastic and non-nociplastic conditions (AUCs 0.73-0.75). Participants who had widespread pain or reported more presumed nociplastic conditions scored higher on all scales ( p s <.001, d s=0.35–1.37). NociQ scales demonstrated small-to-moderate correlations with measures of theoretically distinct constructs ( r s=0.10–0.44), supporting discriminant validity, and explained additional variance in pain intensity beyond those measures (Δ R²s =.02-.07; p s <.05), supporting incremental validity. Discussion: Results indicate four nociplastic pain characteristics, including two, location variability and exacerbation by thoughts and emotions, psychometrically validated here for the first time. The 16-item NociQ demonstrates promising reliability and validity as a brief questionnaire of nociplastic pain. Future research should examine its clinical utility, such as in matching patients to pain mechanism-targeted treatments.
- 26 October 2026
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
Nociplastic Questionnaire (NociQ)
Objectives: Nociplastic pain is implicated in many chronic pain conditions, yet it has been defined primarily by the absence of structural causes—a diagnosis by exclusion. No validated nociplastic pain questionnaire exists. This study examined hypothesized pain-specific features of nociplastic pain and developed a brief self-report instrument, the Nociplastic Questionnaire (NociQ). Methods: We generated items based on literature review and input from experts and individuals with lived experience. We administered the items and measures of other pain-related constructs (pain intensity/interference, catastrophizing, kinesiophobia, and perceived stress) to 888 participants with diverse chronic pain conditions. Results: Factor analyses supported four dimensions captured by internally consistent 4-item subscales (αs ≥0.74): 1) location variability, 2) exacerbation by thoughts and emotions, 3) widespreadness, and 4) allodynia. The NociQ total score adequately discriminated presumed nociplastic and non-nociplastic conditions (AUCs 0.73-0.75). Participants who had widespread pain or reported more presumed nociplastic conditions scored higher on all scales ( p s <.001, d s=0.35–1.37). NociQ scales demonstrated small-to-moderate correlations with measures of theoretically distinct constructs ( r s=0.10–0.44), supporting discriminant validity, and explained additional variance in pain intensity beyond those measures (Δ R²s =.02-.07; p s <.05), supporting incremental validity. Discussion: Results indicate four nociplastic pain characteristics, including two, location variability and exacerbation by thoughts and emotions, psychometrically validated here for the first time. The 16-item NociQ demonstrates promising reliability and validity as a brief questionnaire of nociplastic pain. Future research should examine its clinical utility, such as in matching patients to pain mechanism-targeted treatments.
- Open Access
Selective Nerve Block of A- or C-Afferents Confirms Dual Role in Touch Pleasantness but Not Touch-Pain Modulation
Gentle and deep pressure are distinct types of touch that often elicit pleasant sensations and modulate pain. Although touch pleasantness has traditionally been attributed to unmyelinated C-tactile afferents, growing evidence suggests an important contribution of myelinated A-fibers. However, the relative role of A- and C-fibers in touch-evoked pleasantness and pain modulation remains unclear. To test the role of A- and C-fibers in touch pleasantness, healthy adults underwent selective peripheral nerve block of the superficial radial nerve to preferentially impair either A- or C-fiber function. Touch pleasantness of brushing (Study 1; N = 24) or deep pressure (Study 2; N = 24) and touch-induced modulation of heat pain were assessed before and after the nerve block. Both nerve blocks significantly reduced the perceived pleasantness of both gentle brushing and deep pressure, supporting a substantial contribution of myelinated A-fibers and well as unmyelinated C-fibers (presumably C-tactile fibers) to affective touch. In addition, block of A-fibers did not diminish touch-induced modulation of experimental heat pain, suggesting a particular pain-inhibiting role for C-tactile fibers. These findings supply causal evidence in healthy adults that myelinated A-fibers are highly involved in touch pleasantness—alongside C-tactile fibers—but are not involved in touch-induced pain relief. Key Points: Unmyelinated C-tactile afferents are thought to relay the pleasantness of touch, however growing evidence suggests myelinated A-afferents may also play a role. Preferential nerve block of either A- or C-fibers reduced the perceived pleasantness of gentle brushing and deep pressure. A-fiber nerve block did not alter touch-induced modulation of heat pain. These findings suggest both A- and C-fibers are involved in touch pleasantness, but point to a pain-inhibiting role of C-tactile afferents.
Open AccessSelective Nerve Block of A- or C-Afferents Confirms Dual Role in Touch Pleasantness but Not Touch-Pain Modulation
Gentle and deep pressure are distinct types of touch that often elicit pleasant sensations and modulate pain. Although touch pleasantness has traditionally been attributed to unmyelinated C-tactile afferents, growing evidence suggests an important contribution of myelinated A-fibers. However, the relative role of A- and C-fibers in touch-evoked pleasantness and pain modulation remains unclear. To test the role of A- and C-fibers in touch pleasantness, healthy adults underwent selective peripheral nerve block of the superficial radial nerve to preferentially impair either A- or C-fiber function. Touch pleasantness of brushing (Study 1; N = 24) or deep pressure (Study 2; N = 24) and touch-induced modulation of heat pain were assessed before and after the nerve block. Both nerve blocks significantly reduced the perceived pleasantness of both gentle brushing and deep pressure, supporting a substantial contribution of myelinated A-fibers and well as unmyelinated C-fibers (presumably C-tactile fibers) to affective touch. In addition, block of A-fibers did not diminish touch-induced modulation of experimental heat pain, suggesting a particular pain-inhibiting role for C-tactile fibers. These findings supply causal evidence in healthy adults that myelinated A-fibers are highly involved in touch pleasantness—alongside C-tactile fibers—but are not involved in touch-induced pain relief. Key Points: Unmyelinated C-tactile afferents are thought to relay the pleasantness of touch, however growing evidence suggests myelinated A-afferents may also play a role. Preferential nerve block of either A- or C-fibers reduced the perceived pleasantness of gentle brushing and deep pressure. A-fiber nerve block did not alter touch-induced modulation of heat pain. These findings suggest both A- and C-fibers are involved in touch pleasantness, but point to a pain-inhibiting role of C-tactile afferents.
- Open Access
- 11 June 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2)
International Pain and Spine Intervention Society Emergency Protocols: Intra-arterial Injection
- 11 June 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2)
Open AccessInternational Pain and Spine Intervention Society Emergency Protocols: Intra-arterial Injection
- Open Access
- 5 June 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2) , 100790
International Pain and Spine Intervention Society Emergency Protocols: Traumatic Spinal Cord Injury
- 5 June 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2) , 100790
Open AccessInternational Pain and Spine Intervention Society Emergency Protocols: Traumatic Spinal Cord Injury
- Open Access
- 5 June 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2) , 100794
International Pain and Spine Intervention Society Emergency Protocols: Epidural Hematoma
- 5 June 2026
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (2) , 100794
Open AccessInternational Pain and Spine Intervention Society Emergency Protocols: Epidural Hematoma
- Open Access
- 7 May 2026
- Published by Wiley in The Journal of Physiology
Modulation of pain by affective touch: effects of childhood trauma, depression, chronic pain, and spinal segment
Chronic pain is highly prevalent, and non‐pharmacological tools are a crucial part of a multimodal approach to reducing burden of pain. Among these touch‐based interventions such as massage have long been popular, yet their underlying pain‐relieving mechanisms are poorly understood. Touch‐based therapies often involve gentle stroking associated with the C‐tactile afferent pathway and deep pressure. Although chronic pain patients often find touch less pleasant than individuals without pain, the effects of chronic pain on touch‐pain modulation have not been directly studied. In the current study we systematically investigated two affective forms of touch – gentle brushing and deep pressure (compression) – on heat pain perception, testing their effects both within‐segment and between‐segment to explore their neural mechanism. We compared touch–pain modulation effects in pain‐free controls and patients with fibromyalgia (FM), a condition characterized by sensory hypersensitivity and affective alterations, hypothesizing that touch‐pain modulation would be reduced in FM. We further examined the role of trauma and depression, which are highly prevalent in FM. Significant touch‐pain modulation occurred only for between‐segment brushing. No significant differences in touch‐pain modulation were observed between FM patients and controls. Notably, trauma history and depression emerged as the strongest predictors of touch‐pain modulation. These findings suggest that touch‐pain modulation involves supraspinal mechanisms that are preserved in FM and are strongly shaped by trauma history and psychological factors. Our results provide novel insight into biopsychosocial determinants of touch‐related pain relief and its relevance to FM. image Key points: Touch‐based interventions such as massage are common non‐pharmacological approaches for chronic pain, but their mechanisms are poorly understood. Chronic pain patients often exhibit reduced touch pleasantness and endogenous pain modulation, but effects of chronic pain on touch‐pain modulation have not been directly studied. We tested the effects of gentle brushing and deep pressure (compression) on heat pain perception, testing both within‐segment (same dermatome) and between‐segment (between dermatome) conditions in no‐pain controls and patients with fibromyalgia (FM). Brushing significantly reduced heat pain in the between‐segment condition and did not differ by pain status; trauma history and depression emerged as the strongest predictors of touch‐pain modulation. These findings suggest that touch‐pain modulation involves supraspinal mechanisms that are preserved in FM and strongly shaped by trauma history and psychological factors.
- 7 May 2026
- Published by Wiley in The Journal of Physiology
Open AccessModulation of pain by affective touch: effects of childhood trauma, depression, chronic pain, and spinal segment
Chronic pain is highly prevalent, and non‐pharmacological tools are a crucial part of a multimodal approach to reducing burden of pain. Among these touch‐based interventions such as massage have long been popular, yet their underlying pain‐relieving mechanisms are poorly understood. Touch‐based therapies often involve gentle stroking associated with the C‐tactile afferent pathway and deep pressure. Although chronic pain patients often find touch less pleasant than individuals without pain, the effects of chronic pain on touch‐pain modulation have not been directly studied. In the current study we systematically investigated two affective forms of touch – gentle brushing and deep pressure (compression) – on heat pain perception, testing their effects both within‐segment and between‐segment to explore their neural mechanism. We compared touch–pain modulation effects in pain‐free controls and patients with fibromyalgia (FM), a condition characterized by sensory hypersensitivity and affective alterations, hypothesizing that touch‐pain modulation would be reduced in FM. We further examined the role of trauma and depression, which are highly prevalent in FM. Significant touch‐pain modulation occurred only for between‐segment brushing. No significant differences in touch‐pain modulation were observed between FM patients and controls. Notably, trauma history and depression emerged as the strongest predictors of touch‐pain modulation. These findings suggest that touch‐pain modulation involves supraspinal mechanisms that are preserved in FM and are strongly shaped by trauma history and psychological factors. Our results provide novel insight into biopsychosocial determinants of touch‐related pain relief and its relevance to FM. image Key points: Touch‐based interventions such as massage are common non‐pharmacological approaches for chronic pain, but their mechanisms are poorly understood. Chronic pain patients often exhibit reduced touch pleasantness and endogenous pain modulation, but effects of chronic pain on touch‐pain modulation have not been directly studied. We tested the effects of gentle brushing and deep pressure (compression) on heat pain perception, testing both within‐segment (same dermatome) and between‐segment (between dermatome) conditions in no‐pain controls and patients with fibromyalgia (FM). Brushing significantly reduced heat pain in the between‐segment condition and did not differ by pain status; trauma history and depression emerged as the strongest predictors of touch‐pain modulation. These findings suggest that touch‐pain modulation involves supraspinal mechanisms that are preserved in FM and strongly shaped by trauma history and psychological factors.
- 8 January 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Debunking myths in facial pain diagnosis for the pain practitioner
Facial pain disorders, most notoriously trigeminal neuralgia, cause substantial suffering, functional impairment, disability, and impaired quality of life. However, most pain medicine practitioners have had only limited education on the evaluation, diagnosis, and treatment of facial pain. Furthermore, this limited education often contains commonly held myths about facial pain diagnosis. These myths can result in misdiagnoses that lead to ineffective medications, interventions, or surgeries and prolonged pain. Therefore, the American Society of Regional Anesthesia and Pain Medicine’s Headache and Facial Pain Special Interest Group convened a multidisciplinary group of neurologists, anesthesiologists, and dentists to identify and dispel pervasive myths in facial pain diagnosis.
- 8 January 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Debunking myths in facial pain diagnosis for the pain practitioner
Facial pain disorders, most notoriously trigeminal neuralgia, cause substantial suffering, functional impairment, disability, and impaired quality of life. However, most pain medicine practitioners have had only limited education on the evaluation, diagnosis, and treatment of facial pain. Furthermore, this limited education often contains commonly held myths about facial pain diagnosis. These myths can result in misdiagnoses that lead to ineffective medications, interventions, or surgeries and prolonged pain. Therefore, the American Society of Regional Anesthesia and Pain Medicine’s Headache and Facial Pain Special Interest Group convened a multidisciplinary group of neurologists, anesthesiologists, and dentists to identify and dispel pervasive myths in facial pain diagnosis.
- Open Access
- 30 December 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (2) , 365-376
Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
Objective: To assess the efficacy of cannabis for the treatment of acute migraine. Background: Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine. Methods: In this randomized, double‐blind, placebo‐controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9‐tetrahydrocannabinol (THC) (THC‐dominant), (2) 11% cannabidiol (CBD) (CBD‐dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pain freedom and most bothersome symptom freedom, all assessed at 2‐h post‐vaporization. Results: Ninety‐two participants were enrolled and randomized, and 247 migraine attacks were treated. THC + CBD was superior to placebo at achieving pain relief (67.2% vs. 46.6%, odds ratio [95% confidence interval] 2.85 [1.22, 6.65], p = 0.016), pain freedom (34.5% vs. 15.5%, 3.30 [1.24, 8.80], p = 0.017), and most bothersome symptom freedom (60.3% vs. 34.5%, 3.32 [1.45, 7.64], p = 0.005) at 2 h, as well as sustained pain freedom at 24 h and sustained most bothersome symptom freedom at 24 and 48 h. THC‐dominant was superior to placebo for pain relief (68.9% vs. 46.6%, 3.14 [1.35, 7.30], p = 0.008) but not pain freedom or most bothersome symptom freedom at 2 h. CBD‐dominant was not superior to placebo for pain relief, pain freedom, or most bothersome symptom freedom at 2 h. There were no serious adverse events. Conclusion: Acute migraine treatment with 6% THC + 11% CBD was superior to placebo at 2‐h post‐treatment with sustained benefits at 24 and 48 h.
- 30 December 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (2) , 365-376
Open AccessVaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
Objective: To assess the efficacy of cannabis for the treatment of acute migraine. Background: Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine. Methods: In this randomized, double‐blind, placebo‐controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9‐tetrahydrocannabinol (THC) (THC‐dominant), (2) 11% cannabidiol (CBD) (CBD‐dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pain freedom and most bothersome symptom freedom, all assessed at 2‐h post‐vaporization. Results: Ninety‐two participants were enrolled and randomized, and 247 migraine attacks were treated. THC + CBD was superior to placebo at achieving pain relief (67.2% vs. 46.6%, odds ratio [95% confidence interval] 2.85 [1.22, 6.65], p = 0.016), pain freedom (34.5% vs. 15.5%, 3.30 [1.24, 8.80], p = 0.017), and most bothersome symptom freedom (60.3% vs. 34.5%, 3.32 [1.45, 7.64], p = 0.005) at 2 h, as well as sustained pain freedom at 24 h and sustained most bothersome symptom freedom at 24 and 48 h. THC‐dominant was superior to placebo for pain relief (68.9% vs. 46.6%, 3.14 [1.35, 7.30], p = 0.008) but not pain freedom or most bothersome symptom freedom at 2 h. CBD‐dominant was not superior to placebo for pain relief, pain freedom, or most bothersome symptom freedom at 2 h. There were no serious adverse events. Conclusion: Acute migraine treatment with 6% THC + 11% CBD was superior to placebo at 2‐h post‐treatment with sustained benefits at 24 and 48 h.
- Open Access
- 30 November 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (12) , 817-917
Consensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group
Background: The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ complex pain, the advent of radiofrequency ablation (RFA) and a host of minimally invasive surgical techniques. Yet, there is no standardization on diagnosis and treatment paradigms. Methods: In February 2023, the Boards of Directors for the American Academy of Pain Medicine (AAPM) and American Society of Regional Anesthesia & Pain Medicine (ASRA-PM) approved the development of multispecialty guidelines on SIJ complex pain. Thirty partner organizations with clinical and scientific interests in SIJ complex pain were identified, and formal letters of request-for-participation were sent to each, along with a request for nominees to serve on the committee. Twenty five organizations agreed to participate in addition to the Departments of Defense and Veterans Affairs. A steering committee developed 21 questions, which spanned criteria for diagnosis, non-interventional and interventional treatments including surgery, technical parameters on how to optimize results, and what constitutes positive outcomes. Questions were methodically assigned to specialized modules comprising 4-5 members with complementary expertise, who collaborated with the Subcommittee Lead and one of three Committee Chairs to develop preliminary drafts. Following thorough revisions, these drafts were subsequently submitted to the full committee for comprehensive review. A modified Delphi method was used in which the answers to questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was achieved. During a committee meeting before commencement, it was agreed that recommendations would be noted when there was >50% agreement among committee members, but that a formal recommendation would require ≥75% consensus. Results: Twenty-one organizations formally endorsed the guidelines. The American Society of Anesthesiologists, and American Academy of Physical Medicine & Rehabilitation, and the North American Spine Society affirmed the benefit of the guidelines but did not officially endorse them. The American Academy of Neurology declined to affirm the benefit of the guidelines citing “lack of relevance to their membership.” Per policies, while the Departments of Defense and Veterans Affairs did not formally review the guidelines for endorsement, their representatives approved them. In addition to being endorsed or the benefit affirmed by all voting organizations, complete consensus from committee members was obtained on all 21 questions. On 2 recommendations, there were dissensions from 3 societies who thought that selecting patients for sacral lateral branch RFA and minimally invasive fusion should be based on ≥75% relief from 2 blocks instead of at least 50% relief from a single block before RFA, and greater than 50% pain relief with documented functional improvement after a single block before fusion. One additional society (Latin American Society of Regional Anesthesia) abstained on the statement that the evidence is stronger for extra-articular than intra-articular injections. The committee found that a battery of physical exam tests has reasonable sensitivity, but lower specificity, for identifying intra-articular but not extra-articular pathology, with negative tests having greater predictive value than positive ones. Intra-articular injections have diagnostic validity for SIJ intra-articular, but not extra-articular pain. There is unclear or negative evidence for imaging. The prevalence rates of intra-articular and extra-articular pathology are comparable, with both intra- and extra-articular steroid injections providing at least 4 weeks of relief in well-selected patients. However, the evidence is slightly stronger for extra-articular corticosteroid injections to provide short-term relief. The evidence base for non-interventional therapies is indirect, extrapolated mostly from low back pain studies. There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief. There is strong evidence for sacral lateral branch RFA to provide relief for at least 6 months in individuals with extra-articular pathology, with face validity and indirect evidence from randomized trials supporting sacral lateral branch blocks as a prognostic tool. There is stronger evidence for larger lesions or more aggressive lesioning strategies than for less stringent techniques. There is weak evidence to support non-steroidal anti-inflammatory drugs to prevent neuritis after RFA, and in most cases anticoagulation does not require cessation in the periprocedural perioid. With an aggressive lesioning strategy, sensory stimulation provides minimal therapeutic benefit, with weak, extrapolated evidence that motor stimulation can provide safety benefit. The cutoff to designate diagnostic or prognostic blocks as positive is most commonly set at 50%, with higher values not shown to improve outcomes for more definitive procedures; for therapeutic treatment outcomes, the evidence supports a lower threshold of ≥30% pain relief or meaningful benefit on non-pain outcomes (eg, opioid cessation) for designation of a positive response. For carefully selected patients with intra-articular SIJ complex pain based on controlled blocks who have failed conservative therapies, there is weak or very weak evidence that minimally invasive SIJ fusion can provide benefit for at least one year. Conclusions: SIJ complex pain remains an underappreciated source of chronic low back pain, affecting between 15% and 30% of patients with axial pain predominantly below L5. Answers to many...
- 30 November 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (12) , 817-917
Open AccessConsensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group
Background: The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ complex pain, the advent of radiofrequency ablation (RFA) and a host of minimally invasive surgical techniques. Yet, there is no standardization on diagnosis and treatment paradigms. Methods: In February 2023, the Boards of Directors for the American Academy of Pain Medicine (AAPM) and American Society of Regional Anesthesia & Pain Medicine (ASRA-PM) approved the development of multispecialty guidelines on SIJ complex pain. Thirty partner organizations with clinical and scientific interests in SIJ complex pain were identified, and formal letters of request-for-participation were sent to each, along with a request for nominees to serve on the committee. Twenty five organizations agreed to participate in addition to the Departments of Defense and Veterans Affairs. A steering committee developed 21 questions, which spanned criteria for diagnosis, non-interventional and interventional treatments including surgery, technical parameters on how to optimize results, and what constitutes positive outcomes. Questions were methodically assigned to specialized modules comprising 4-5 members with complementary expertise, who collaborated with the Subcommittee Lead and one of three Committee Chairs to develop preliminary drafts. Following thorough revisions, these drafts were subsequently submitted to the full committee for comprehensive review. A modified Delphi method was used in which the answers to questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was achieved. During a committee meeting before commencement, it was agreed that recommendations would be noted when there was >50% agreement among committee members, but that a formal recommendation would require ≥75% consensus. Results: Twenty-one organizations formally endorsed the guidelines. The American Society of Anesthesiologists, and American Academy of Physical Medicine & Rehabilitation, and the North American Spine Society affirmed the benefit of the guidelines but did not officially endorse them. The American Academy of Neurology declined to affirm the benefit of the guidelines citing “lack of relevance to their membership.” Per policies, while the Departments of Defense and Veterans Affairs did not formally review the guidelines for endorsement, their representatives approved them. In addition to being endorsed or the benefit affirmed by all voting organizations, complete consensus from committee members was obtained on all 21 questions. On 2 recommendations, there were dissensions from 3 societies who thought that selecting patients for sacral lateral branch RFA and minimally invasive fusion should be based on ≥75% relief from 2 blocks instead of at least 50% relief from a single block before RFA, and greater than 50% pain relief with documented functional improvement after a single block before fusion. One additional society (Latin American Society of Regional Anesthesia) abstained on the statement that the evidence is stronger for extra-articular than intra-articular injections. The committee found that a battery of physical exam tests has reasonable sensitivity, but lower specificity, for identifying intra-articular but not extra-articular pathology, with negative tests having greater predictive value than positive ones. Intra-articular injections have diagnostic validity for SIJ intra-articular, but not extra-articular pain. There is unclear or negative evidence for imaging. The prevalence rates of intra-articular and extra-articular pathology are comparable, with both intra- and extra-articular steroid injections providing at least 4 weeks of relief in well-selected patients. However, the evidence is slightly stronger for extra-articular corticosteroid injections to provide short-term relief. The evidence base for non-interventional therapies is indirect, extrapolated mostly from low back pain studies. There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief. There is strong evidence for sacral lateral branch RFA to provide relief for at least 6 months in individuals with extra-articular pathology, with face validity and indirect evidence from randomized trials supporting sacral lateral branch blocks as a prognostic tool. There is stronger evidence for larger lesions or more aggressive lesioning strategies than for less stringent techniques. There is weak evidence to support non-steroidal anti-inflammatory drugs to prevent neuritis after RFA, and in most cases anticoagulation does not require cessation in the periprocedural perioid. With an aggressive lesioning strategy, sensory stimulation provides minimal therapeutic benefit, with weak, extrapolated evidence that motor stimulation can provide safety benefit. The cutoff to designate diagnostic or prognostic blocks as positive is most commonly set at 50%, with higher values not shown to improve outcomes for more definitive procedures; for therapeutic treatment outcomes, the evidence supports a lower threshold of ≥30% pain relief or meaningful benefit on non-pain outcomes (eg, opioid cessation) for designation of a positive response. For carefully selected patients with intra-articular SIJ complex pain based on controlled blocks who have failed conservative therapies, there is weak or very weak evidence that minimally invasive SIJ fusion can provide benefit for at least one year. Conclusions: SIJ complex pain remains an underappreciated source of chronic low back pain, affecting between 15% and 30% of patients with axial pain predominantly below L5. Answers to many...
- 17 September 2025
- Published by Elsevier in The Spine Journal
- Vol. 25 (10) , 2353-2354
Response to letter to the Editor regarding “Common interventional procedures for chronic non-cancer spine pain: a systematic review and network meta-analysis of randomised trials.”
- 17 September 2025
- Published by Elsevier in The Spine Journal
- Vol. 25 (10) , 2353-2354
Response to letter to the Editor regarding “Common interventional procedures for chronic non-cancer spine pain: a systematic review and network meta-analysis of randomised trials.”